Advertisement
New Zealand markets closed
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NZD/USD

    0.5942
    -0.0007 (-0.12%)
     
  • NZD/EUR

    0.5555
    +0.0015 (+0.27%)
     
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • OIL

    84.02
    +0.45 (+0.54%)
     
  • GOLD

    2,350.20
    +7.70 (+0.33%)
     
  • NASDAQ

    17,718.58
    +288.08 (+1.65%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • Dow Jones

    38,254.68
    +168.88 (+0.44%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • NZD/JPY

    93.6370
    +1.1410 (+1.23%)
     

What Does Teva’s Recently Announced Restructuring Plan Entail?

What Does Teva’s Recently Announced Restructuring Plan Entail?

On December 14, 2017, Teva (TEVA) stock gained more than 10% on the back of the announcement of a comprehensive restructuring plan and additional measures to improve the company’s operational and financial performance. On December 14, 2017, the Generic Drugs ETF (GNRX) rose by approximately 1.0%. Teva Pharmaceuticals has a debt of $32 billion, which needs to be serviced in an organized manner to strengthen the company’s financials and bring down leverage.